Venkatesan Jay 4

4 · Serina Therapeutics, Inc. · Filed Jun 22, 2026

AI-generated summary of this filing

Updated Jun 22, 2026

Serina (SER) Director Venkatesan Jay Converts Preferred, Buys Stock

What Happened

Venkatesan Jay, a director of Serina Therapeutics (SER), completed a mandatory conversion of Series A Convertible Preferred Stock into common shares and made a small open‑market purchase. He acquired 224,152 common shares via conversion (priced at $2.25, value $504,342) and bought 589 common shares on the open market on 2026-05-22 at $1.78 ($1,048). The filing also reports a 15,250‑share derivative award (no cash paid) and the disposition/surrender of 96,525 Series A preferred shares as part of the conversion process (valued at $217,181 on a $2.25 basis).

Key Details

Transaction dates and prices:
- 2026-05-22: Open‑market purchase (P) — 589 shares @ $1.78 = $1,048.
- 2026-06-17: Conversion of derivative security (C) — acquired 224,152 common shares @ $2.25 = $504,342.
- 2026-06-17: Conversion of derivative security (C) — disposed/surrendered 96,525 Series A preferred shares @ $2.25 = $217,181 (derivative).
- 2026-06-17: Grant/award (A) — 15,250 derivative shares (no cash paid); subject to vesting terms.
Footnotes of note:
- F2: The conversion was triggered upon shareholder approval on June 17, 2026; the Series A preferred converted into common stock at an adjusted conversion price of $2.25.
- F1: The filing corrects a prior Form 4 administrative error about direct vs indirect ownership.
- F3: The 15,250 derivative award vests on the earlier of the day before the next annual meeting or one year after grant, subject to continued service.
- F4: The Series A preferred is perpetual (no expiration).
Shares owned after the transactions are not explicitly detailed in this filing; the report also corrects a prior ownership reporting error.
Timeliness: The Form 4 was filed 2026-06-22 covering transactions dated 2026-05-22 and 2026-06-17. The reporting appears late relative to the usual 2‑business‑day Form 4 deadline.

Context

The large activity on June 17 was an automatic conversion of preferred shares into common shares after shareholder approval, not a market purchase — it increases common‑share holdings but is a recapitalization event rather than a personal buy/sell decision. The small May 22 open‑market buy (~$1k) is a modest insider purchase. The 15,250‑share award is a derivative grant with a vesting schedule; it does not reflect an immediate market sale.

Form 4

Period: 2026-05-22

Director

Transactions

Purchase
Common Stock
[F1]
2026-05-22$1.78/sh+589$1,048→ 589 total
Conversion
Common Stock
[F2][F1]
2026-06-17$2.25/sh+224,152$504,342→ 231,705 total(indirect: By Trust)
Award
Stock Option (right to buy)
[F3]
2026-06-17+15,250→ 15,250 total
Exercise: $1.98Exp: 2036-06-17→ Common Stock (15,250 underlying)
Conversion
Series A Convertible Preferred Stock
[F4]
2026-06-17$2.25/sh−96,525$217,181→ 0 total(indirect: By Trust)
Exercise: $5.18From: 2025-04-08→ Common Stock, $0.0001 par value (222,222 underlying)

Footnotes (4)

[F1]The share ownership amount has been adjusted to correct an administrative error in a prior Form 4 filed by the Reporting Person, which inadvertently reported 7,553 shares as direct ownership, rather than indirect ownership.
[F2]Shares reflect the mandatory conversion at an adjusted Conversion Price of $2.25 of the Company's Series A Convertible Prefered Stock ("Series A Preferred") issued in connection with the April 2025 Private Placement. The Reporting Person was originally issued 96,525 shares of Series A Preferred that were converted into 222,222 shares of Common Stock and 1,930 shares that were issued for payment of accrued dividends. Shares were issued upon receipt of stockholder approval, which approval was obtained on June 17, 2026, thereby triggering the automatic conversion of the Series A Preferred into common stock.
[F3]The stock options will vest on the earlier of (i) the day before the next Annual Meeting or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.
[F4]The Series A Convertible Preferred Stock is perpetual and therefore has no expiration date.

Signature

/s/ Steven Ledger, Attorney in Fact|2026-06-22

2 files